NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT05296564 2025-10-02Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersHadassah Medical OrganizationPhase 1/2 Recruiting3 enrolled
NCT02774291 2023-08-04Anti-NY ESO-1 mTCR Peripheral Blood LymphocytesAlbert Einstein College of MedicinePhase EARLY_PHASE1 Terminated3 enrolled 6 charts
NCT01967823 2021-03-24T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed11 enrolled 12 charts
NCT00795678 2013-08-02Chemotherapeutic Agents in Brain/BreastCase Comprehensive Cancer CenterCompleted10 enrolled